Related Experiment Video

Updated: May 19, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

Wei Tian1, Junqing Chen, Haifei He

  • 1Department of Surgical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 24, 2012
PubMed

Insights

MicroRNAs (miRNAs) are key regulators of breast cancer drug resistance, impacting treatment failure. Targeting these miRNAs offers a promising strategy to overcome resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a leading cause of cancer mortality in women.
  • Drug resistance significantly hinders effective systemic therapy for breast cancer.
  • MicroRNAs (miRNAs) are increasingly recognized as critical regulators in cancer development and progression.

Purpose of the Study:

  • To elucidate the role of miRNAs in mediating breast cancer drug resistance.
  • To explore the potential of miRNAs as biomarkers for predicting treatment response and prognosis.
  • To investigate miRNA-targeted therapeutic strategies for overcoming drug resistance.

Main Methods:

  • Review of preclinical research on miRNA involvement in multidrug resistance.
  • Analysis of miRNA-mediated endocrine resistance mechanisms.
  • Evaluation of miRNA roles in modulating key signaling pathways and cellular processes.

Main Results:

  • MiRNAs regulate drug resistance by affecting drug efflux transporters, anti-apoptotic proteins, epithelial-mesenchymal transition, and cancer stem cells.
  • MiRNAs mediate endocrine resistance by modulating Estrogen Receptor alpha (ERα) expression and related signaling pathways.
  • MiRNAs influence cell survival and apoptosis in the context of drug resistance.

Conclusions:

  • MiRNAs are central players in the development of breast cancer drug resistance.
  • MiRNAs hold potential as predictive biomarkers for systemic therapy response and patient prognosis.
  • Targeting specific miRNAs represents a promising therapeutic avenue to overcome drug resistance in breast cancer.

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...